Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

SXTP

60 Degrees Pharmaceuticals Inc

May 21 • 12:03PM ET

0.2800

Dollar change +0.0010
Percentage change 0.36	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.17	Insider Own	23.45%	Shs Outstand	12.14M	Perf Week	27.27%
Market Cap	3.40M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	8.62%	Shs Float	9.29M	Perf Month	11.46%
Income	-0.80M	PEG	-	EPS next Q	-0.23	Inst Own	3.51%	Short Float	1.23%	Perf Quarter	-9.68%
Sales	0.38M	P/S	8.95	EPS this Y	62.07%	Inst Trans	-	Short Ratio	0.48	Perf Half Y	-59.72%
Book/sh	-0.23	P/B	-	EPS next Y	58.18%	ROA	-8.53%	Short Interest	0.11M	Perf Year	-
Cash/sh	0.24	P/C	1.18	EPS next 5Y	-	ROE	-	52W Range	0.20 - 8.65	Perf YTD	-72.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-10.89%	52W High	-96.76%	Beta	-
Dividend TTM	-	Quick Ratio	6.77	Sales past 5Y	2.28%	Gross Margin	-23.44%	52W Low	39.23%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	7.16	EPS Y/Y TTM	-	Oper. Margin	-1463.65%	RSI (14)	64.68	Volatility	15.83% 10.53%
Employees	3	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-211.57%	Recom	2.00	Target Price	1.30
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	109.50%	Payout	-	Rel Volume	3.34	Prev Close	0.28
Sales Surprise	685.87%	EPS Surprise	115.79%	Sales Q/Q	580.65%	Earnings	May 15 BMO	Avg Volume	240.52K	Price	0.28
SMA20	22.30%	SMA50	12.42%	SMA200	-58.39%	Trades		Volume	339,220	Change	0.36%

May-20-24 07:59AM	60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study (GlobeNewswire) +24.06%
May-15-24 09:55PM	SXTP Stock Earnings: 60 Degrees Reported Results for Q1 2024 (InvestorPlace)
01:45PM	60 Degrees Pharmaceuticals Announces First Quarter 2024 Results (GlobeNewswire)
May-08-24 07:59AM	60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases (GlobeNewswire) +8.54%
May-02-24 07:59AM	60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required (GlobeNewswire)
07:58AM	Loading…
Apr-03-24 07:58AM	60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis (GlobeNewswire)
Mar-14-24 07:59AM	60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024 (GlobeNewswire) -7.30%
Feb-20-24 07:59AM	60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris (GlobeNewswire)
Feb-08-24 07:59AM	60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer (GlobeNewswire)
Jan-31-24 12:00PM	WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering (PR Newswire) -8.75%
11:15AM	60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering (GlobeNewswire)
Jan-30-24 09:45AM	WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering (PR Newswire) -40.58%
09:00AM	60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering (GlobeNewswire)
Jan-22-24 07:59AM	60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting (GlobeNewswire) +19.97%
Jan-16-24 07:59AM	60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
07:59AM	Loading…
Dec-26-23 07:59AM	60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024 (GlobeNewswire) +28.09%
Nov-15-23 07:29AM	60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease (GlobeNewswire) +17.93%
Oct-19-23 08:31AM	60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston (GlobeNewswire) +8.15%
Oct-12-23 04:16PM	60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases (GlobeNewswire) -5.42%
Sep-18-23 04:16PM	60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements (GlobeNewswire)
Sep-06-23 07:31AM	60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 09:00AM	Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Aug-30-23 07:32AM	60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity (GlobeNewswire) +7.04%
Aug-22-23 07:31AM	60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria (GlobeNewswire) -5.92%
Aug-15-23 07:31AM	60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov (GlobeNewswire) +7.23%
Jul-31-23 07:59AM	60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects (GlobeNewswire) +6.16%
Jul-21-23 09:00AM	60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE) -8.56%
Jul-14-23 01:30PM	WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit (PR Newswire) -15.67%
12:39PM	60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering (GlobeNewswire)
Jul-12-23 01:45PM	WallachBeth Capital Announce Pricing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit (PR Newswire)
12:29PM	Loading…
12:29PM	60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering (GlobeNewswire)

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
XU CHERYL	Director	Jan 31 '24	Buy	0.38	200,000	75,000	424,934	Feb 02 03:31 PM
DOW GEOFFREY S	President and CEO	Jan 31 '24	Buy	0.38	25,974	9,740	703,599	Feb 02 03:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SXTP

60 Degrees Pharmaceuticals Inc

Upgrade your FINVIZ experience